Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.78B |
$22.71
-1.09%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.72B |
$33.23
+0.62%
|
|
ADPT
Adaptive Biotechnologies Corporation
Antibody Discovery Platform cited as part of Immune Medicine R&D capabilities.
|
$2.67B |
$17.51
-1.52%
|
|
DNLI
Denali Therapeutics Inc.
DNL310 and DNL126 are recombinant enzymes delivered via Denali's TransportVehicle platform, representing its core product categories.
|
$2.63B |
$17.98
-4.26%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.58B |
$6.99
-3.79%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.52B |
$19.94
-2.87%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$2.50B |
$41.44
+0.41%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$2.48B |
$27.87
-1.87%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$2.48B |
$23.86
-1.30%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$2.47B |
$71.00
-0.06%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.38B |
$16.70
+1.74%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.36B |
$27.08
-0.81%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.32B |
$21.80
+0.02%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$2.28B |
$8.75
+0.57%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.26B |
$42.52
+1.35%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.21B |
$33.52
-1.50%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$2.17B |
$13.65
-2.95%
|
|
MLYS
Mineralys Therapeutics, Inc.
Lorundrostat is an orally administered small-molecule therapeutic targeting aldosterone synthesis for hypertension, classifiable as an Oral Small Molecule Therapeutic.
|
$2.17B |
$32.75
+4.37%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$2.17B |
$22.50
-4.26%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.09B |
$21.50
+0.07%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$2.08B |
$36.18
-0.63%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$2.07B |
$15.02
-1.02%
|
|
SRPT
Sarepta Therapeutics, Inc.
Directly develops gene therapies (ELEVIDYS) and other gene therapy programs; gene therapy is Sarepta's core biotech focus.
|
$2.06B |
$21.13
-0.84%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.04B |
$18.57
-1.33%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$2.03B |
$4.66
+0.43%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.01B |
$17.47
-1.47%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$2.01B |
$33.26
+0.51%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.00B |
$5.84
-4.80%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.96B |
$11.27
-0.13%
|
Showing page 6 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
